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Abstract 
Italy has recently introduced regulations that profoundly change the arrangement of 
ethics committees. Specifically, their numbers have been reduced from more than 200 
to a few dozen.The decree defining the criteria for their composition and functioning 
includes regulations intended to improve efficiency and efficacy. The present article 
provides a brief overview of the new provisions and identifies some critical aspects.
INTRODUCTION
The law of 8 November 2012 [1] required each Ital-
ian region to reorganise its ethics committees by 30 
June 2013 in line with criteria laid down in the relevant 
decree subsequently published on 8 February 2013 un-
der the title “Criteria for the composition and function-
ing of ethics committees” [2].
The law and the decree introduce significant changes 
in the organisation of ethics committees.
Among the motivations for this law were the exces-
sive number of ethics committees in Italy (243 in 2012 
[3]) and the Health Ministry’s intention to simplify and 
rationalise the complicated regulatory framework gov-
erning clinical trials of drugs in Italy.
The law of 8 November 2012 [1] required that each 
region should reorganise the ethics committees operat-
ing in its confines in line with the following criteria:
- the jurisdiction of each ethics committee should in-
clude one or more provinces, based on a ratio of one 
committee per one million inhabitants, subject to the 
possibility of an additional ethics committee with re-
sponsibility for one or more Institutes of Care and Sci-
entific Research (IRCCS);
- in deciding which committees to retain, the region 
must take into account the numbers of so-called 
“single opinions” (pareri unici, i.e. opinions given by 
the committee affiliated to the healthcare institution 
in which the coordinating researcher is employed) 
issued during the last three years;
- each committee’s terms of reference may include 
clinical trials not only of drugs but also of medical 
devices, surgical procedures and food products;
- the independence of each committee and the ab-
sence of hierarchical relationships between commit-
tees must be guaranteed.
The implementing decree of 8 February 2013 [2] de-
fined the operating criteria and confirmed the deadline 
of 30 June 2013 as the date by which the regions must re-
organise their respective networks of ethics committees. 
The key measures contained in the decree are:
- committee members must have proven knowledge 
and experience in clinical trials of drugs and medical 
devices, as well as in other matters covered by the 
remit of the ethics committee (Article 2.5); 
- appointments are for three years and can be re-
newed consecutively only once (Article 2.8);
- outside consultants may be invited to advise on spe-
cific issues on an ad hoc basis (Article 2.6);
- each committee must comprise at least: three cli-
nicians; one locally-practising physician in general 
medicine; one paediatrician; one biostatistician; 
one pharmacologist; one pharmacist employed 
by the local regional health service; the medical 
director or scientific director of the institution 
concerned; one specialist in legal and insurance 
matters or a forensic scientist; one bioethicist; one 
representative of the healthcare specialisation in-
volved in the trial; one representative of volunteer 
or patient protection associations; one expert in 
medical devices; one clinical engineer; one nutri-
tion specialist; one specialist in novel technical and 
invasive and semi-invasive diagnostic and thera-
peutic procedures; one geneticist (Article 2.5); the 
committees’ independence must be guaranteed: by 
the absence of any form of hierarchical subservi-
ence to the institution with which they are affiliat-
ed; by drawing at least one third of their members 
from outside the institution; by the absence of any 
conflicts of interest (Article 3).
On the basis of these provisions, each region has im-
plemented a decree to establish the ethics committees 
that will operate within its territory.
Given the complexity of the pre-existing situation, 
the need to review the organisation of ethics commit-
tees was widely acknowledged and appropriate meas-
ures have been taken, but some aspects of the criteria 
laid down in the new decree [2] nonetheless invite 
comment.
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ON THE CRITERIA FOR IDENTIFYING 
HEALTHCARE FACILITIES WITH ETHICS 
COMMITTEES
Notwithstanding the recognised need to reduce the 
extravagant number of ethics committees previously 
operating in Italy, the drastic reduction implemented 
by combining several pre-existing committees together 
could have untoward effects, two of which merit atten-
tion. The first is the excessive workload assigned to the 
new committees: the second is that in many cases the 
committee will no longer be located on the site where 
the research is conducted. 
In addition, two of the criteria for redrawing the map 
of these committees could possibly be improved.
The first refers to population density and envisages 
one committee for each million inhabitants (Article 
2.1). However, this parameter does not take into con-
sideration the uneven distribution throughout Italy of 
institutions that conduct clinical trials. In some regions 
of Northern Italy there is a high density of hospitals, 
universities, Institutes of Care and Scientific Research 
(IRCCS) and industries active in the field of experi-
mentation, while in some regions of Southern Italy 
there are very few.
The second criterion used by the regions, in accord-
ance with the decree, to establish which ethics commit-
tees to retain and which to suppress, is a quantitative 
one (Article 2.2): the committees that have produced 
the highest numbers of pareri unici in the shortest time 
over the last three years have been confirmed. The use 
of criteria based on efficiency appears further to rein-
force the bureaucratic nature that these committees 
have gradually acquired over the years. Since their in-
ception as advisory bodies they have gradually assumed 
the guise of licensing agencies, a situation that fosters 
the perception by researchers that they are a hindrance 
to freedom in research, assigned to tiresome regulatory 
formalities. This criterion also fails to consider the nu-
merous forms of non-pharmacological research such 
as research using biological samples, epidemiological 
studies or public health research.
ON THE COMPOSITION
OF THE COMMITTEES
The decree obliges the committees to include experts 
in some disciplines (Article 2.5) that are rarely subject 
to scrutiny by ethics committees (except in institutions 
specialising in them): nutrition and medical devices, for 
instance, are areas in which most institutions only rarely 
conduct trials. The decree also appears not to oblige all 
specialist members to take part in all committee meet-
ings, their presence being required only when the pro-
tocols under examination relate to their specific fields. 
This could complicate the task of calculating the quo-
rum necessary for a session to be valid. It would perhaps 
have been preferable to allow the committees, where 
necessary, to call on external specialists in the specific 
fields, as provided in the previous regulations [4]. In ad-
dition, the presence of only one expert in ethics on an 
ethics committee of nearly 20 members seems a serious 
under-representation.
Rather than require the presence on these commit-
tees of experts in areas that may well be involved only 
rarely in trials, it would perhaps have been appropriate 
to identify a minimum number of places to be filled by 
experts in required fields and allow the committees to 
assign the remaining places according to the specific 
characteristics of the institute of affiliation.
Finally, the decree requires that “no less than one 
third of the total” members should be “external to the 
healthcare institution for which the ethics committee 
operates” (Article 3.2). The previous regulations (de-
cree of 12 May, 2006 [4]) required that “at least one 
half of the total members should not be employed in the 
institution by which the committee is engaged”. This 
reduction in the minimum number of external members 
does nothing to encourage the independence of ethics 
committees.
ON SOME PRACTICAL ASPECTS
There are other provisions in the decree [2] that 
could be improved:
- the decree calls for the compensation agreements 
relating to trials to be signed on the same day as, or 
within three days of, the meeting of the ethics com-
mittee during which the trial is given the go-ahead 
(Article 2.9). This is effectively unfeasible. As the 
procedure leading to the Administrator’s signature 
is usually set in motion only after the institution has 
received formal notification of a committee’s opin-
ion, there is usually a time lag. It would therefore 
be more appropriate to allow the Administration 
to assess the compensation agreements, leaving to 
the ethics committee the task only of verifying its 
congruity with the trial protocol;
- the decree assigns to ethics committees the function 
of evaluating clinical trials, although it adds that they 
“may propose initiatives for the training of healthcare 
operators in matters relating to bioethics” (Article 1). 
It would instead be desirable to assign them func-
tions of monitoring, consultancy and the promotion 
of initiatives in the area of research ethics;
- the decree provides for the costs incurred by eth-
ics committees to be covered by the sums paid by 
commercial sponsors for the evaluation of proto-
cols (Article 6.3): it would be preferable for these 
expenses to be included among the overheads of 
the institute of affiliation;
- the new regulations fail to solve the problem of 
evaluation and consultancy in the field of clinical 
practice. This calls for resources and responsibili-
ties that could be assigned to special committees 
distinct and separate from those for the assessment 
of trials. An approach of this kind was adopted in 
the Veneto region in 2004 [5].
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